Taisho sees Mexican OTC acquisitions as N American springboard
This article was originally published in Scrip
Helped by the strong yen, the year to date has seen a record value of overseas acquisitions by Japanese firms across all sectors, and Taisho Pharmaceutical is doing its bit to raise the total even further.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.